The Trump administration's handling of reproductive rights remains uncertain as recent comments from Robert F. Kennedy Jr. suggest a shift in strategy towards investigating mifepristone safety. This inquiry offers Trump a delay in addressing abortion rights, potentially waiting until after the 2026 midterms. Anti-abortion advocates are pressuring for action on abortion pills, with proposals from lawmakers like Sen. Josh Hawley seeking stricter FDA regulations. Kennedy's remarks imply that significant changes in abortion policy might only evolve from White House initiatives, thus holding key influence over future decisions.
"Investigation has emerged as the administration's strategy on abortion, with RFK prompting an inquiry into mifepristone's safety, possibly to delay decisions on reproductive rights."
"Most recently, Sen. Josh Hawley has proposed a bill on mifepristone, directing the FDA to impose new restrictions and allowing lawsuits against prescribers and pharmacies."
Collection
[
|
...
]